AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03435692
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Oxycodone was administered as needed for breakthrough pain post operatively.
Trial: NCT03435692
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
Trial: NCT00821587
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
Trial: NCT00821587
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
Trial: NCT01597609
Drug: sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg, taken orally once per day for 12 weeks
Trial: NCT03134378
Drug: Rabeprazole Sodium 20mg
RxNorm normalized name: Rabeprazole Sodium 20mg Oral tablet, gastro-resistant
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03134378
Drug: Amoxicillin 500 Mg
RxNorm normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT02182050
Drug: BIBF 1120 ES low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02745353
Drug: naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02774265
Drug: VTE prophylaxis with Enoxaparin 30mg BID
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Trial: NCT02774265
Drug: VTE prophylaxis with Aspirin 81mg BID
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Trial: NCT02781090
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches
Trial: NCT00913848
Drug: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
RxNorm normalized name: valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913848
Drug: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
RxNorm normalized name: divalproex sodium 500 MG [Depakote]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03390582
Drug: Methimazole Pill
RxNorm normalized name: methimazole Pill
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
Trial: NCT01254305
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
Trial: NCT01208103
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given CVC
Trial: NCT02726399
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
Trial: NCT02726399
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
Trial: NCT01766115
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HCV Protease Inhibitor
Trial: NCT02726399
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80mg/m2 administered as an IV infusion every 21 days
Trial: NCT00573950
Drug: cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
Trial: NCT02551653
Drug: [11C]-GSK2256098 500 MBq
DrugBank: GSK2256098 (DB16106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
Trial: NCT00418548
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00451724
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03361605
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration
Trial: NCT00162916
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg or 40mg, once daily, for 40 weeks
Trial: NCT04037657
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
Trial: NCT00912821
Drug: 6 L dialysate
RxNorm normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 L peritoneal dialysis solution
Trial: NCT00912821
Drug: 8 L dialysate
RxNorm normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 L peritoneal dialysis solution
Trial: NCT01644084
Drug: Hydroxyethyl starch 130/0.4
RxNorm normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
Trial: NCT02449551
Drug: Volitinib
RxNorm normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
Trial: NCT00980109
Drug: active oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
Trial: NCT01158079
Drug: ALN-VSP02
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
Trial: NCT01641159
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
Trial: NCT00436605
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00980109
Drug: zanamivir for inhalation
RxNorm normalized name: zanamivir Inhalant Product
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Trial: NCT00695682
Drug: intravitreal injection of infliximab
RxNorm normalized name: infliximab Injection
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
Trial: NCT02580773
Drug: Prophylactic anticoagulation ( INNOHEP®)
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
Trial: NCT02580773
Drug: Curative anticoagulation ( INNOHEP®)
RxNorm normalized name: tinzaparin sodium Injectable Solution [Innohep]
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
Trial: NCT01907074
Drug: Cholates
RxNorm normalized name: cholate
DrugBank: Berberine ursodeoxycholate (DB18111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholates is given intravenously (IV push) and by mouth, once per study visit
Trial: NCT04438096
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 100 mg pills (QD) will be orally administered for 12 weeks
Trial: NCT00433576
Drug: resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02199223
Drug: regorafenib + panitumumab
RxNorm normalized name: Regorafenib
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00297505
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01594775
Drug: Syntocinon (Oxytocin) nasal spray
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Trial: NCT00886795
Drug: abatacept (Orencia ®)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
Trial: NCT02837003
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Trial: NCT02837003
Drug: Thienopyridine
RxNorm normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Trial: NCT01217177
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00853944
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
Trial: NCT00163280
Drug: ATL-104
RxNorm normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
Trial: NCT01208649
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
Trial: NCT00571467
Drug: PRTX-100 (Staphylococcal protein A)
RxNorm normalized name: Protein-type A microspheres
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg
Trial: NCT00818779
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 - 300 mg once daily for 6 weeks
Trial: NCT00818779
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 mg once daily for 6 weeks
Trial: NCT01592695
Drug: Nicotine replacement therapy - transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01592695
Drug: Nicotine replacement therapy - nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01592695
Drug: Nicotine replacement therapy - nicotine lozenge
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01592695
Drug: Bupropion Sustained Release
RxNorm normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01592695
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01518153
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 by vein on Day -6 to -3.
Trial: NCT01518153
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m\^2 by vein on Day -2.
Trial: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Trial: NCT01518153
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg by vein on Day -1.
Trial: NCT01518153
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
Trial: NCT01518153
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
Trial: NCT02421575
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00229138
Drug: EC-MPS, Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03775928
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib 425mg qd po
Trial: NCT01632540
Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
RxNorm normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
Trial: NCT00644670
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Trial: NCT00644670
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Trial: NCT02766673
Drug: Albuterol Sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Trial: NCT03376555
Drug: Local Heating (LH)
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
Trial: NCT02870829
Drug: menaquinone-7
RxNorm normalized name: menaquinone-7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement given post dialysis 3x/week
Trial: NCT03376555
Drug: Flow Mediated Dilation with nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Trial: NCT00625651
Drug: AMG 655
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
Trial: NCT00625651
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
Trial: NCT03675841
Drug: Pazufloxacin Mesilate ear drops
RxNorm normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
Trial: NCT01734850
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan
Trial: NCT01073644
Drug: Sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib 50 mg, 4 weeks on, 2 weeks off